8-K current report · filed Nov 4, 2026

Bio-rad Laboratories Inc (BIO) 8-K Current Report: November 4, 2026

Item EX-99.2Item EX-99.1Item 2.02Item 7.01BIO overview

Short answer

Bio-rad Laboratories Inc (BIO) filed an 8-K current report with the SEC on November 4, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q3 2026 results for quarter ended September 30, 2026 announced November 4, 2026.

Bio-rad Laboratories Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 4, 2026
  • Supplemental Earnings Presentation provides additional investor detail under Item 7.01
  • Full financial metrics and management commentary are in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Supplemental earnings presentation covers Bio-Rad’s quarter ended September 30, 2026
  • Investor-relevant financial detail is contained in Exhibit 99.2 and the company’s Investor Relations website

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $656.4M, up 0.5% reported and 0.7% currency-neutral, signaling stabilization after prior declines
  • Clinical Diagnostics revenue $401.8M, up 2.8% currency-neutral, offsetting Life Science’s 2.4% decline
  • Non-GAAP operating margin 12.8% versus 11.8%, with operating income $83.7M versus $77.0M
  • GAAP net income $458.6M, or $17.02 per share, primarily boosted by a $588.2M equity-security valuation gain
  • 2026 outlook maintained: currency-neutral revenue decline of 3.0% to growth of 0.5%, non-GAAP operating margin 10.0% to 12.0%

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $656M, up 0.5% reported and 0.7% currency-neutral, indicating modest top-line growth
  • GAAP operating margin (7.6%), pressured by $77M restructuring and $50M intangible impairment charges
  • Non-GAAP operating margin 12.8% and gross margin 54.5%, both up 100 basis points year over year
  • Clinical Diagnostics revenue $402M, up 2.7% year over year, offsetting Life Science revenue decline of 2.8% to $255M
  • Full-year outlook: currency-neutral revenue growth ranges from (3.0)% to +0.5%, with free cash flow guidance of $290M to $340M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bio-rad Laboratories Inc 8-K filings

Get the next BIO 8-K as it lands

Follow BIO for push alerts, or ask the research agent what this filing means.